Dr. Reddy's Biosimilar Ambition
India-based drug makers, who have built themselves into regional powerhouses thanks to their efforts in creating small molecules generics, are keenly interested in the biosimilar opportunity. But none has been as aggressive-or as brash - as Dr. Reddy's Laboratories. (This is a sidebar to the article "Opening A Door To Biosimilars In the US."
You may also be interested in...
With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.
Researchers say “no strong” evidence shows high vitamin D intake is beneficial to preventing or treating COVID-19, but adequate levels are needed to support immunity. Other researchers say countries should increase recommended vitamin D levels with “very suggestive” evidence supporting its effect against COVID-19 severity.
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.